ABSTRACT. The tyrosine content of parenteral solutions parenteral infusion of human infants. Accordingly, we tested is limited by poor tyrosine solubility. N-acetyl-L-tyrosine whether N-Ac-Tyr, a less expensive soluble tyrosine derivative, has excellent solubility and is a potential source of intra-was utilized as a tyrosine source during parenteral nutrition in venous tyrosine. Infusion of N-acetyl-U-I4C-L-tyrosine as adult rats. part of a total parenteral nutrition regimen in the rat at a level of 0.5 mmol/kg/day resulted in rapid labeling of tissue tyrosine pools, production of I4Co2, incorporation of I4C- Cystine and tyrosine have been suggested as essential amino acids for some premature infants (1-3). Both amino acids have limited solubility, and cannot be added to total parenteral nutrition solutions in quantities sufficient to meet the infant requirements. The absence of these amino acids results in depressed cystine and tyrosine levels in many infants infused with such solutions (4-6).
N-acetyl-L-U-I4C-tyrosine was prepared from U-I4C-L-tyrosine (New England Nuclear, Boston, MA) and acetic anhydride by the method of Sheehan and Yang (10) and purified by recrystallization from ethyl acetate-benzene mixtures. The composition of the compound was checked by amino acid analysis before and after acid hydrolysis (6 N HCl, 1 lO" C, 24 h).
Healthy male Sprague-Dawley rats weighing 300 to 400 g were used for all experiments. Utilization of N-Ac-Tyr was first tested in five animals after intraperitoneal injection of 0.5 mmol of NAc-Tyr per kilogram body weight [15 pCi N-acetyl-L-(U-14C)tyrosine] dissolved in 1 ml of isotonic saline. After injection, the rats were immediately placed in a glass metabolism chamber and the labeled carbon dioxide collected as described by Palese and Tephly (1 1) at 0.5, 1, 2, 4, 8, 12, and 24 h.
Since studies of N-Ac-Tyr injected intraperitoneally showed reasonable utilization, the compound was also studied when infused as part of a parenteral nutrition regimen. Rats were cannulated using the method of Popovic and Popovic (12) under ether anesthesia and allowed to recover from the operative procedure for a 2-day period. This cannulation procedure allows simultaneous sampling of arterial blood while the nutrient solution is infused into the venous circulation.
After recovery, the animals were placed in restraining metabolism cages and alimented parenterally using the solution described by Steiger et al. (1 3) . The base solution was prepared by adding sterile 50% dextrose solution to an 8.5% solution of crystalline amino acids (FreAmine, McGaw Laboratories, Glendale, CA) 2:l. This solution (33% glucose-2.8% amino acids) does not contain tyrosine. The solution was infused into the venous cannula at a rate of 50 to 55 ml/kg/day by pump (Extracorporal Medical Specialties, Bridgeport, PA). Total daily energy intake was between 73 to 80 kcal, sufficient to provide maintenance requirements of adult rats (13, 14) .
Three groups of five animals each were studied. The first group (group I) was infused with the parenteral solution without added N-Ac-Tyr. The second and third groups were infused with the same parenteral solution to which N-Ac-Tyr was added at levels providing either 0.5 (group 11) or 2.0 (group 111) mmol/kg body weight per 24 h infusion. Sufficient N-a~etyl-U-~~C-~-tyrosine was added so that 15 pCi were infused per 24 h in each case. The solutions were sterilized by passage through a 0.22-p membrane filter (Millipore Corporation, Bedford, MA) before infusion.
Sequential 4-h urine samples were collected in iced graduate cylinders during the infusion, and deproteinized immediately with sulfosalicylic acid (15) . Blood samples (0.5 ml) were drawn from the arterial cannula at 0 and 24 h, heparinized, and centrifuged to separate plasma and erythrocytes. Plasma and erythrocyte samples were prepared and analyzed for amino acid content as described previously (8, 9) . Simultaneous radioactivity and amino acid analyses were carried out as described by Stegink (1 6) .
At the end of the parenteral infusion, the animals were lightly anesthetized with ether, and tissue samples (liver, kidney, muscle, intestine, brain, stomach, heart, lung, spleen) were quickly excised, blotted, and weighed. The remaining carcass was skinned. One-gram portions of each tissue were homogenized in 10 ml of 5% sulfosalicylic acid for 3 min in a Virtis microhomogenizer. The precipitated protein was removed by centrifugation at 20,000
x g for 15 min at 4" C in a refrigerated centrifuge , and aliquots of the supernatant solution were assayed for radioactivity and amino acid distribution as described by Stegink (16) . The entire skin and remaining carcass were similarly treated.
The total radioactivity present in plasma, urine, tissue, and carcass homogenates was determined by adding aliquots of the homogenate to 10 ml of scintillation fluid (17) . The values were quench corrected. Background noise was eliminated by counting an appropriate portion of control urine, plasma, or tissue homogenates. The quantity of radioactivity present in protein fractions of the samples was determined by dissolving a specific weight of precipitated protein in hyamine hydroxide (Packard Instrument Co., Downers Grove, IL) followed by digestion for 48 h at 37" C before counting.
The distribution of radioactivity between the various amino acids in the protein fraction of plasma and tissues was determined after acid hydrolysis. The precipitated protein (from the sulfosalicylic acid homogenate) was collected by centrifugation, suspended in 5 ml of 3.5% sulfosalicylic acid, and the protein was again collected by centrifugation. The supernatant solution was discarded and the procedure repeated three times to remove any traces of free tyrosine or N-Ac-Tyr. The precipitated protein was then dissolved in 6 N HCI in a hydrolysis tube. The tube was evacuated using a vacuum pump and then flushed with dry, oxygen-free nitrogen gas. After repeating the process three times, the tube was sealed and the protein hydrolyzed for 22 h at 1 15" C. The hydrolysate was lyophilized to dryness, the residue dissolved in 5% sulfosalicylic acid, and this solution then subjected to the simultaneous radioactivity-amino acid analysis procedure (16) .
Statistical analysis of the data was canied out using the paired t test and the Student's t test (1 8) .
RESULTS
Utilization of N-Ac-Tyr was first tested by intraperitoneal injection of 0.5 mmol/kg body weight N-Ac-Tyr into five adult rats. The results were compared with those obtained in previously studied animals (8) injected with an equimolar quantity of AlaTyr. The rate of I4C-carbon dioxide release from animals injected with these two compounds is shown in Figure 1 . Injection of either compound resulted in rapid labeling of expired carbon dioxide. Radioactive carbon dioxide release peaked within 30 min after injection and declined rapidly. However, the rate of 14C-carbon dioxide release was more rapid with Ala-Tyr than with N-Ac-Tyr. Table 1 shows the radioactivity distribution 24 h after intraperitoneal injection of N-Ac-Tyr. In general results were similar to those obtained earlier with Ala-Tyr; 41.2% of the label present in N-Ac-Tyr was expired as carbon dioxide and 8.31% was excreted in urine. The carcass accounted for most of the remaining label. Urinary losses were higher in animals given N-Ac-Tyr than those noted previously in animals injected with Ala-Tyr (4.6%). When the distribution of radioactivity in the urine of animals injected with N-Ac-Tyr was examined, 90% of the radioactivity in the urine was present as N-Ac-Tyr, while 10% was present as free tyrosine. In animals injected with Ala-Tyr, 92% of the radioactivity in urine was present as tyrosine and only 8% as Ala-Tyr (8) . Urinary free tyrosine excretion vvas significantly higher ( p < 0.05) in rats injected with N-Ac-1Tyr
(0.29 k 0.08 1*rno1/24 h) than in control rats injected with isotonic saline (0.17 f 0.09 1*rno1/24 h).
Concentrations of free amino acids in plasma 24 h after injection did not differ significantly between control animals injected with isotonic saline and test animals injected intraperitoneally with N-Ac-Tyr.
Since the data obtained after intraperitoneal injection were promising, N-Ac-Tyr utilization was investigated when infused at 0.5 and 2.0 mmol/kg body weight as part of a total parenteral nutrition regimen. The results obtained were compared with values obtained earlier (8, 9) in animals treated with a simrlar regimen to which Ala-Tyr had been added at 0.5 and 2 mmol/ kg body weight as the tyrosine source.
Studies were first camed out in animals infused with N-AcTyr at 0.5 mmol/kg body weight (group 11). Plasma amino acid levels, both before parenteral alimentation, and after 24-h infusion are shown in Table 2 . In general, plasma levels of those amino acids present in the parenteral solution increased frcom fasting levels noted in preinfusion samples to levels considered postprandial in samples taken after 24 h infusion. Plasma levels of those amino acids not present in the parenteral solution remained at fasting levels or decreased. No differences in the response of these plasma amino acids were noted between solutions (+ N-Ac-Tyr). The addition of N-Ac-Tyr to the parenteral solution at 0.5 mmol/kg body weight/day did not significantly increase plasma tyrosine levels over baseline values. We had previously noted that Ala-Tyr infused at 0.5 mmol/kg body weight also failed to increse plasma tyrosine concentrations (9) . The infusion of radioactively labeled compounds made it possible to evaluate utilization of N-Ac-Tyr for both energy production (C02) and protein synthesis. The data in Table 3 demonstrate utilization of parenterally administered N-Ac-Tyr. Animals infused with 0.5 mmol/kg body weight N-Ac-Tyr oxidized 36% of the infused label, losing 10% in the urine. Of the radioactivity lost in urine, 74% was present as N-Ac-Tyr and 23% was present as tyrosine. Urinary losses of infused label were greater in these animals infused with N-Ac-Tyr than values noted when 0.5 mmol/kg body weight Ala-Tyr was used as the tyrosine source. In those previously studied animals (9), 42% of the infused label was oxidized and 7.7% was lost in the urine (74% was tyrosine and 26% Ala-Tyr).
These data clearly demorlstrated utilization of N-Ac-Tyr as a tyrosine source for both tissue-free tyrosine pools and protein synthesis. After 24 h infusion of N-Ac-Tyr at 0.5 mmol/kg body weight, 53% of the infused label was present in tissue as either free or protein-bound tyrosine; muscle, liver, plasma, intestine, and kidney accumulated substantial amounts of radioactivity. The results are similar to those noted earlier in animals infused with Ala-Tyr at 0.5 mmol/kg body weight (9) . Determination of the radioactivity distribution between the free amino acid fraction, the protein bound fraction, and the free N-Ac-Tyr content of the various tissue fractions showed 10 to 20% of the radioactivity present as free tyrosine, with the remainder in proteinbound form after 24 h infusion. Only trace quantities of radioactivity were detected at the free N-Ac-Tyr position. Isolation of protein from liver, plasma, and muscle extracts, followed by acid hydrolysis, and analysis for distribution of radioactivity among the various amino acids demonstrated that 94 to 99% of the radioactivity present in the protein was tyrosine. These data demonstrate incorporation of labeled intact tyrosine into protein.
Labeling did not result from conversion of tyrosine into nonessential amino acids with subsequent incorporation of nonessential amino acids into protein.
Although good utilization of N-Ac-Tyr was noted when infused at 0.5 mmol/kg body weight as part of parenteral feeding regimen, the quantity of N-Ac-Tyr infused was not sufficient to increase plasma tyrosine concentrations above fasting levels (overall mean 67.8 k 7.42 pM). Thus, group III animals were infused with a parenteral regimen providing N-Ac-Tyr at 2.0 mmol/kg body weight. Plasrna amino acid concentrations in these animals are shown in Table 2 . Plasma amino acid concentrations of those amino acids present in the parenteral mixture increased during infusion, as noted in control rats infused with the parenteral nutrition solution alone without a tyrosine source, while levels of amino acids not present in the solution remained constant or decreased. Infusion of N-Ac-Tyr at 2.0 mmol/kg significantly ( p < 0.05) increased plasma tyrosine concentrations over both baseline values and levels noted in control animals infused with the parenteral nutrition solution alone without an added tyrosine source. Plasma tyrosine concentrations increased from a mean baseline value of 7 1 + 20 to 14 1 + 16 pM after 24 h infusion with 2 mmol/kg body weight N-Ac-Tyr. The latter value is similar to that noted in animals infused with 2 mmol/ kg body weight Ala-Tyr ( 1 14 1 21 pM) (9) .
The distribution of radioactivity in these animals is shown in Table 3 . At this level of infusion 25.6% of infused N-Ac-Tyr was oxidized to carbon dioxide and 16.8% was excreted in the urine (82% N-Ac-Tyr; 18% tyrosine). The rate of tyrosine oxidation to carbon dioxide was lower and the rate of urinary loss greater than values noted in previously studied animals infused with Ala-Tyr at 2.0 mmol/kg body wcight (9) . Animals infused with 2 mmol/kg body wcight Ala-Tyr oxidized 54% of infused label and excreted only 5.4% in the urine (45% Ala-Tyr, 55% tyrosine).
Radioactivity from N-Ac-Tyr was found in all tissues studied. Determination of the radioactivity distribution between the free amino acid fraction, the protein bound fraction, and free N-AcTyr content of the various tissue fractions showed that 10 to 20% of the radioactivity was present as free tyrosine, with the remainder in protein-bound form after 24 h infusion. Only trace quantities of radioactivity were detected at the free N-Ac-Tyr position in most tissues. Plasma was an exception, and 15% of the total radioactivity was found in the free N-Ac-Tyr position. Isolation of protein from iiver, plasma, and muscle extracts, followed by acid hydrolysis, and analysis for distribution of radioactivity among the various amino acids demonstrated that 94 to 99% of the radioactivity incorporated into protein was tyrosine. Thcse data demonstrate incorporation of labeled intact tyrosine into protein. Labeling did not result from conversion of tyrosine into nonessential amino acids with subsequent incorporation of nonessential amino acids into protein.
DISCUSSION
The evidcnce for metabolic utilization of tyrosine when administered as N-Ac-Tyr consists of three elements. First, 25 to 36% of the radioactivity administered appears as I4C-carbon dioxide when N-Ac-Tyr was administered as part of the parenteral regimen at either 0.5 or 2.0 mmol/kg body weight per day. This clearly indicates hydrolysis of N-Ac-Tyr and oxidation of the tyrosine. Second, the increased plasma tyrosine levels noted during infusion of N-Ac-Tyr at 2.0 mmol/kg body weight per day, and the presence of radioactivity as tyrosine in the free amino acid pools of both plasma and tissues indicates its availability. Finally, and most importantly from the perspective of growth and tissue repair, radioactive tyrosine was incorporated into both plasma and tissue proteins as tyrosine, and proteinbound tyrosine accounted for 80 to 90% of the radioactivity found in these tissues. The data demonstrate that tyrosine provided as N-Ac-Tyr is rapidly metabolized when administered as part of a parenteral alimentation solution and provides free tyrosine for energy substrate, tissue tyrosine pools, and protein synthesis.
However, utilization of N-Ac-Tyr as a parenteral tyrosine sourcc appeared somewhat less than that observed with equimolar quantities of Ala-Tyr (8, 9) . The percentage of infused labeled tyrosine oxidized to I4C-carbon dioxide was lower for NAc-Tyr than for Aia-Tyr at both infusion levels (36.3 versus 42.4% at 0.5 mmol/kg body weight: 25.6 vrrszrs 54.1 % at 2.0 mmol/kg body weight). Similarly, urinary losses were greater with N-Ac-Tyr than with Ala-Tyr (10. 1 v~r s~~. r 7.7% at 0.5 mmol/ kg body weight; 16.8 v~r . s~~. s 5.4% at 2.0 mmol/kg body weight). These data indicate that N-Ac-Tyr is hydrolyzed more slowly by adult rats than Ala-Tyr.
Urinary tyrosine excretion was increased in animals infused with parenteral solutions containing N-Ac-Tyr when compared to values noted in animals infused with the same solution without added N-Ac-Tyr. This increased urinary loss of tyrosine was not due to an "overflow" aminoaciduria in animals infused at 0.5 mmol/kg body weight of N-Ac-Tyr per day because plasrna tyrosine levels did not differ from those noted in control animals infused without N-Ac-Tyr. The increased urinary losses of tyrosine noted in animals infused at 2 mmol N-Ac-Tyr/kg body weight per day may reflect the increased plasma tyrosine levels observed in these animals. In general, the loss of urinary tyrosine in N-Ac-Tyr-infused animals was similar to that noted in anim,als infused with equimolar quantities of Ala-Tyr in earlier studies (8, 9) .
Animals infused with N-Ac-Tyr lost greater quantities of the infused tyrosine source in urine than animals infused with AlaTyr. For example, in animals infused with Ala-Tyr at 0.5 mmol/ kg body weight, 26% of the radioactivity excreted in urine was Ala-Tyr while 74% was tyrosine. Animals infused with ;!. O mmoljkg body weight Ala-Tyr lost 45% of the total radioactivity excreted as Ala-Tyr and 55% as free tyrosine. In contrast, animals infused with N-Ac-Tyr at 2 mmol/kg body weight per day excreted most of the label as intact N-Ac-Tyr (74% at 0.5 mmc~l/ kg; 82% at 2.0 mmol/kg).
N-Ac-Tyr was not initially considered as a potential source of iv tyrosine in our studies, although it was soluble and easy to synthesize. We expected that its metabolism would be much less rapid than that of tyrosine peptides. Mammalian tissues contain N-acyl-amidohydrolases that catalyze the hydrolysis of N-acyl bonds of N-acetylated or N-formylated amino acids. The best described enzyme is acylase I, found in large amounts in the kidney (19) (20) (21) (22) . Although acylase I has good activity toward Nacyl-L-methionine and N-acyl-L-glutamate, it has little activity toward N-Ac-Tyr. Acylase 11, a less well-described amidohydrolase (2 1, 23, 24), catalyzes the hydrolysis of N-acetyl-L-asparta.te, but has little activity toward N-Ac-Tyr. Thus, the lack of reactivity of N-Ac-Tyr with these enzyme systems delayed our consideration of it as a tyrosine source. However, after our experiments with Ala-Tyr were completed, Endo (25) reported that mammalian tissues contain acylase 111, which preferentially catalyzes the hydrolysis of the N-acyl derivatives of aromatic amino acids. Although the relative amounts of the three acylase enzymes in mammalian tissues have not been determined, our studies suggest sufficient acylase I11 activity for utilization of N-Ac-Tyr as a tyrosine source, at least in adult rats.
The studies outlined above indicate reasonable utilization of N-Ac-Tyr as a tyrosine source, but indicate that urinary excretion may limit utilization at higher infusion levels. It is important to recognize that our studies involved short-term infusion. It is possible that continued excretion of N-Ac-Tyr during long-term, high-dose infusion may produce some untoward metabolic effect not seen in short-term studies. At the present time a number of new amino acid solutions contain N-Ac-Tyr. but few utilizat~on data in humans are available.
Snyderman (2) has presented evidence suggesting that tyrosine is an essential amino acid for some premature infants, even in the presence of adequate phenylalanine intake. Snyderman has estimated the tyrosine requirements for such orally fed infants to be 50 to 120 mg/kg/day (2, 26). Extrapolation of her clral feeding data to parenteral alimentation suggests the need for 50 to 120 mg (0.3 to 0.66 mmol) of tyrosine per 100 ml of solution, assuming an infusion rate of 100 to 120 ml/kg/24 h of standard parenteral solution of 2.5% amino acids-25% glucose. N-Ac-Tyr is very soluble and can be added to parenteral amino acid solutions in quantities sufficient to provide 2.5 mmo1/100 mi of a 10% solution of amino acids. When such a solution is diluted with glucose to make the final 2% solution of amino acids, the final solution would contain 0.5 mmo1/100 ml of N-Ac-Tyr. The solubility of N-Ac-Tyr would even permit development of the compound as an additive for iv solutions in a manner similar to that currently used for electrolytes.
